# BARDA Funds Bundibugyo Ebola Vaccine

On October 28, 2026, IAVI received a $36 million award under a U.S. government contract with a ceiling of up to $99 million to advance a single-dose vaccine candidate for the Bundibugyo strain of Ebola. The work includes manufacturing doses for clinical testing and outbreak response, conducting an early-stage trial, and developing an updated candidate. Hilleman Laboratories, SK bioscience, and IDT Biologika are also identified as participating organizations. Separately, an October 26 extended agreement provides additional supply of an Ebola treatment through Regeneron.

- The awards cover complementary Ebola countermeasures: vaccine development and manufacturing capacity, plus additional treatment supply.
- IAVI and the participating organizations indicate potential work across clinical development, vaccine manufacturing, and preparedness for outbreak response; contractors with relevant capabilities may find opportunities in these areas.
- The vaccine contract’s $99 million ceiling is not the same as the $36 million award. Procurement teams and industry stakeholders should distinguish the initial award from the potential contract ceiling when assessing the program’s scale.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding, Emergency Response
**Published:** October 28, 2026

### Government Entities
- Biomedical Advanced Research and Development Authority (BARDA)

### Vendors
- IAVI (awardee)
- Hilleman Laboratories ()
- SK bioscience ()
- IDT Biologika ()
- Regeneron (provider of additional Ebola treatment supply under an extended agreement)

### Sources
- [Research organization IAVI receives US funding for Ebola vaccine development | The Mighty 790 KFGO | KFGO](https://kfgo.com/2026/10/28/research-organization-iavi-receives-us-funding-for-ebola-vaccine-development) - The Mighty 790 KFGO